Barclays analyst Jack Meehan upgraded Myriad Genetics (MYGN) to Equal Weight from Underweight and raised his price target for the shares to $40 from $18 following this morning's positive coverage decision by UnitedHealth (UNH).
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here